Overview

First-In-Human Study of EOS884448 in Participants With Advanced Cancers.

Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.
Phase:
Phase 1
Details
Lead Sponsor:
iTeos Belgium SA
iTeos Therapeutics